#GLP-1 class
Coverage of the GLP-1 receptor agonist family and its successors.
GLP-1 constipation: prevalence vs incidence
A 2026 study argues many GLP-1 users had constipation before starting treatment, inflating the headline rate.
Tirzepatide CV biomarkers in SURMOUNT-1
A SURMOUNT-1 post hoc analysis found tirzepatide reduced CRP, IL-6, leptin, and PAI-1 at 72 weeks. What the biomarker shifts mean, and what they do not.
15-PGDH and muscle loss on GLP-1 drugs
A Stanford mouse study finds that inhibiting 15-PGDH preserved muscle repair during semaglutide weight loss without reducing fat loss.
GLP-1 and GIP drugs in fat cells
A 2026 review maps what GLP-1 and dual GIP/GLP-1 agonists do inside human adipocytes, and finds most evidence still comes from rodent models.
Anti-dementia drugs in 2026: what works
A German review covers old-line dementia drugs, new amyloid antibodies, and why semaglutide failed in two large Alzheimer's trials.
CagriSema vs tirzepatide for obesity
A network meta-analysis of 25 trials ranked tirzepatide 15 mg and CagriSema as the top weight-loss treatments. But direct trial data tells a different story.
DNA-based GLP-1 delivery via MYO Technology
A single injection of plasmid DNA encoding GLP-1 produced sustained weight loss for over a year in obese mice. What the data shows.
Eli Lilly wins over Noom GLP-1 dose claims
The NAD recommended Noom drop its 'A Smaller Dose. A Smarter Start' tagline after Eli Lilly challenged the claim as unsupported by evidence.
GLP-1 drugs and lipedema: early evidence
A 2026 Dermatologic Surgery review found only two studies of GLP-1 receptor agonists in lipedema. The rationale is real, but the clinical evidence is thin.
Semaglutide in type 1 diabetes: Danish data
Danish registry data on 879 people with T1D who started semaglutide: HbA1c fell 0.52%, with no rise in hypoglycaemia or DKA hospitalisations.
EMA backs extending Mounjaro to children with type-2 diabetes
On 11 December 2025 the EMA's CHMP recommended extending Mounjaro's licensed indication to adolescents and children aged 10 and over with insufficiently controlled type-2 diabetes.
Mounjaro and Zepbound: same drug, different names. Here is why
Mounjaro and Zepbound are both Eli Lilly's tirzepatide. Same molecule, same doses, different brands sold for different indications. The marketing split is regulatory, not pharmacological.